Are you misusing IVIGs in your system?
Intravenous immune globulins (IVIGs) represent $1.7 billion in annual spend for U.S. health systems. With nine major brands and over 100 documented off-label uses, health systems need to take a critical look at standardizing use.
Download this case study to:
- Learn how one health system saved $500K by eliminating multiple IVIG brands
- Explore how an academic medical center stopped excessive off-label use
- Understand why clinical evidence is the key to tackling inappropriate drug utilization